Third Harmonic Bio, Inc. financial data

Symbol
THRD on Nasdaq
Industry
Pharmaceutical Preparations
Location
1700 Montgomery Street, Suite 210, San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 4.55K % -16.4%
Debt-to-equity 3.2 % +2.56%
Return On Equity -16.5 % -47.8%
Return On Assets -16 % -47.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 45.1M shares +10.8%
Common Stock, Shares, Outstanding 44.9M shares +11.9%
Entity Public Float 299M USD +247%
Common Stock, Value, Issued 5K USD +25%
Weighted Average Number of Shares Outstanding, Basic 41.7M shares +5.26%
Weighted Average Number of Shares Outstanding, Diluted 41.7M shares +5.26%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 36.5M USD +52.3%
General and Administrative Expense 22.4M USD +11.9%
Operating Income (Loss) -58.9M USD -33.9%
Nonoperating Income (Expense) 13.4M USD +2.08%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -45.5M USD -47.5%
Earnings Per Share, Basic 1.09 USD/shares +39.7%
Earnings Per Share, Diluted 1.09 USD/shares +39.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 285M USD +5.94%
Assets, Current 291M USD +6.64%
Deferred Income Tax Assets, Net 38.2M USD +49.8%
Property, Plant and Equipment, Net 130K USD -23.1%
Operating Lease, Right-of-Use Asset 3.04M USD -19.2%
Other Assets, Noncurrent 448K USD -49.1%
Assets 295M USD +6.08%
Accounts Payable, Current 1.94M USD +5.39%
Liabilities, Current 7.11M USD +31.2%
Operating Lease, Liability, Noncurrent 2.35M USD -26.8%
Liabilities 9.46M USD +9.65%
Retained Earnings (Accumulated Deficit) -160M USD -39.8%
Stockholders' Equity Attributable to Parent 285M USD +5.97%
Liabilities and Equity 295M USD +6.08%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.29M USD +5.72%
Net Cash Provided by (Used in) Financing Activities 49K USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 44.9M shares +11.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.24M USD +6.46%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 286M USD +5.93%
Deferred Tax Assets, Valuation Allowance 38.2M USD +49.8%
Deferred Tax Assets, Gross 39.1M USD +46.7%
Operating Lease, Liability 3.21M USD -18.8%
Depreciation 12K USD +300%
Payments to Acquire Property, Plant, and Equipment 0 USD
Lessee, Operating Lease, Liability, to be Paid 3.77M USD -22.9%
Property, Plant and Equipment, Gross 214K USD +4.9%
Operating Lease, Liability, Current 859K USD +15.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.18M USD +2.71%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.15M USD +2.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 558K USD -39.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.21M USD +2.64%
Deferred Tax Assets, Operating Loss Carryforwards 15.1M USD +25.7%
Preferred Stock, Shares Issued 0 shares
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 238K USD -80.3%
Operating Lease, Payments 1.12M USD +35.1%
Additional Paid in Capital 445M USD +16.1%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 11.1M USD +15.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%